Genpharm provides fast-track market access to rare disease and specialty pharmaceutical companies looking to expand into the Middle East, North Africa, and Türkiye. It is the regional leader in rare diseases and one of the only regional companies to have gene therapy expertise.

Founded in 2012, it, has bases in the Dubai Science Park, UAE, an office in Boston, USA, in the heart of the biotech hub, and in Ireland. Operating through evidence-based medicine and the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions into the MENA region.

In 2023, following its 10th anniversary year, Jameel Health acquired Genpharm expanding our distribution infrastructure and portfolio with Genpharm’s specialism in rare disease therapies.

Genpharm employs highly qualified and experienced MSL and KAM and offers regulatory, medical, PV and logistical support. With extensive knowledge of local business culture and a vast network of trusted partners, Genpharm’s creates market opportunities for innovative healthcare products and services. Current partners include Novartis Gene Therapy, Orchard Therapeutics, Sarepta, PTC, Ultragenyx, Biohaven, Sintetica, Admedus, ABiotics, and others.

Visit: Genpharm